Preliminary results from the phase 2 IPAX-Linz study demonstrate TLX101 (131I-iodofalan) achieved a median overall survival of 12.4 months from treatment initiation in recurrent high-grade glioma patients.
The FDA granted priority review to TLX101-CDx (18F-floretyrosine), a PET imaging agent, for characterizing recurrent or progressive glioma in adults and children.
The FDA has granted priority review to Telix's TLX101-CDx (18F-FET), an imaging agent for progressive or recurrent glioma, with a decision expected by April 26, 2025.
The FDA has granted priority review to Telix Pharmaceuticals' TLX101-CDx (Pixclara; 18F-floretyrosine) for glioma imaging, setting a PDUFA goal date of April 26, 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.